2,432.5
+3.40%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ono Pharmaceutical Co
Its shares trade on Tokyo Stock Exchange under the ticker 4528.T. It has been listed since 1 January 1962. In the fiscal year to 31 March 2026, it reported revenue of ¥515.78bn and net income of ¥69.77bn. At that date it held total assets of ¥1.11trn and shareholders' equity of ¥850.73bn.
Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company is headquartered in Osaka, Osaka-Fu. The firm operates in one business segment. The Pharmaceutical segment involves in the manufacture and sale of drugs for medical and general use. The firm also involves in the clinical development, introduction and derivation of pharmaceuticals.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 1 Jan 1962
- Employees
- 3,560
- Website
- ono.co.jp ↗
Leadership
Pay as last reported
- Mr. Gyo SagaraChairman of the Board, Chief Executive Officer, Representative Director, since 2006¥190.0m
- Dr. Toichi TakinoPresident, Chief Operating Officer, Representative Director, since 2011
- Mr. Toshihiro TsujinakaExecutive Vice President, Chief Director of Business Strategy, Director of Business Design, Director of Sustainability Promotion, Representative Director, since 2016
- Mr. Satoshi TakahagiManaging Executive Officer, Chief Director of Sales, Senior Director of Primary
- Mr. Akira TakadaManaging Executive Officer, Chief Director of CMC & Production
- Mr. Masaki ItoSenior Director of Business Management in Main Business Strategy Unit, Director of Business Management and Accounting in Business Management Unit, President of Subsidiary
- Dr. Hiromu HabashitaExecutive Officer, Deputy Chief Director of Research
- Mr. Yasushi HirotaExecutive Officer, Chief Director of Reliability Assurance
- Mr. Kunihiko ItoExecutive Officer, President of Subsidiary
- Mr. Kiyoji KatsumataExecutive Officer, Chief Director of Research, Senior Director of Research Project
- Mr. Koichi KitadaExecutive Officer, Manager of Osaka Office of Primary Management Unit in Main Sales Unit
- Mr. Tatsuya OkamotoExecutive Officer, Chief Director of Development, Senior Director of Oncology Clinical Development, Manager of Global Development Management Unit
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 86
- Environment
- 99
- Social
- 99
- Governance
- 61
- Direct emissions (scope 1)
- 6,700 t
- Energy emissions (scope 2)
- 9,500 t
- Value chain emissions (scope 3)
- 28,000 t
- Women in the workforce
- 20.30841%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ono Pharmaceutical Co Ltd boasts a strong research and development capability, allowing them to innovate and develop new pharmaceutical products. This enables the company to stay competitive in the market and address evolving healthcare needs.
- The company offers a diverse range of pharmaceutical products across various therapeutic areas. This diversification helps to mitigate risks associated with any single product or therapeutic category, enhancing the company's stability and resilience in the market.
- Ono Pharmaceutical Co Ltd has established a strong market presence in Japan, one of the largest pharmaceutical markets in the world. This gives the company a significant competitive advantage, as it can leverage its brand reputation and distribution networks to capitalize on domestic opportunities.
Weaknesses
- Despite its strong position in Japan, Ono Pharmaceutical Co Ltd has limited international presence compared to some of its global competitors. This restricts their ability to fully capitalize on the potential of international markets and may hinder future growth.
- The company's revenue is heavily dependent on a few key products, which poses a risk if any of these products face regulatory challenges, patent expirations, or stiff competition. This concentration of revenue puts Ono Pharmaceutical Co Ltd at higher risk of financial instability.
Opportunities
- Ono Pharmaceutical Co Ltd has the opportunity to expand its presence in international markets, leveraging its expertise and product portfolio to capture market share outside of Japan. This diversification would create additional revenue streams and reduce dependency on a single market.
- The pharmaceutical industry is continually evolving, and there is a constant demand for innovative therapies. By investing in research and development efforts for novel treatments, Ono Pharmaceutical Co Ltd can position itself at the forefront of medical advancements and gain a competitive edge.
Threats
- The pharmaceutical industry is highly competitive, with numerous global and local players vying for market share. Ono Pharmaceutical Co Ltd faces the threat of intense competition from both established competitors and emerging companies, which could impact its market position and profitability.
- The pharmaceutical industry is subject to rigorous regulations and compliance requirements, which can pose challenges in terms of product development, approval, and market access. Adapting to evolving regulatory standards is essential for Ono Pharmaceutical Co Ltd to maintain compliance and ensure business continuity.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.